Highlights Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

Market Closed - Australian S.E. Other stock markets 02:10:38 2024-05-17 EDT			5-day change	1st Jan Change
4.14 ^AUD	+5.34%		+6.15%	+117.89%

04-24	Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer	MT
04-04	Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes	04-03	MT
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising	03-26	MT
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%	03-21	MT
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial	03-15	CI
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range	03-08	CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA	12-22	CI
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer	11-30	CI
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level	11-30	CI
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE	11-29	CI
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial	11-07	CI
Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III	23-10-26	CI
Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer	23-10-03	CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23	CI
Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure	23-08-10	CI
Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin	23-07-24	CI
Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer	23-07-04	CI
Clarity Pharmaceuticals Establishes US Center of Excellence for Targeted Copper Theranostics	23-06-28	CI
Clarity Pharmaceuticals Commences COMBAT theranostic Prostate Cancer Trial in the US	23-06-20	CI
Clarity Pharmaceuticals Confirms No Supply Interruptions	23-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

Highlights

Filters